Milprosa Vaginal Ring

Generic name:progesterone
Dosage form: vaginal ring

Medically reviewed by Drugs.com. Last updated on Jul 1, 2021.

Indications and Usage for Milprosa Vaginal Ring

MILPROSA™ is indicated to support embryo implantation and early pregnancy (up to 10 weeks post-embryo transfer) by supplementation of corpus luteal function as part of an Assisted Reproductive Technology (ART) treatment program for infertile women up to and including 34 years of age.

Limitation of Use

Efficacy in women 35 years of age and older has not been established.

Milprosa Vaginal Ring Dosage and Administration

Important Dosage and Administration Information

MILPROSA is not recommended for use with other vaginal products (such as antifungal products, vaginal lubricants, diaphragms, and condoms) because this concomitant use has not been studied and may alter the progesterone release and absorption from the vaginal system [see Warnings and Precautions (5.4) and Drug Interactions (7)].

Recommended Dosage and Administration

Insert one MILPROSA vaginal system starting on the day after oocyte retrieval. Leave in place continuously (for a minimum of 23 hours per day) for 7 days, then remove the used MILPROSA and insert a new MILPROSA. Replace MILPROSA weekly for up to 10 weeks.

Dosage Forms and Strengths

Vaginal system: 1.78 grams of progesterone in a white to off-white, flexible, non-biodegradable silicone ring (toroidal-shape). MILPROSA has a cross-sectional diameter of approximately 8.5 mm, and an outer and inner diameter of approximately 55 mm and 38 mm, respectively. Each MILPROSA releases an average of 11 mg/day of progesterone when placed in the vagina over a 7-day period.

Contraindications

MILPROSA is contraindicated in women with:

• Known sensitivity to progesterone or any of the ingredients of MILPROSA [see Description (11)]
• Undiagnosed...